JaLCDOI 10.18926/AMO/54512
フルテキストURL 70_4_317.pdf
著者 Sakurai, Jun| Matsui, Yusuke| Hiraki, Takao| Iguchi, Toshihiro| Fujiwara, Hiroyasu| Gobara, Hideo| Mitsuhashi, Toshiharu| Nagasaka, Takeshi| Susumu Kanazawa, Susumu Kanazawa|
抄録 The present single center prospective phase II clinical trial is designed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for colorectal lung metastases. Patients who have colorectal lung metastases without extrapulmonary metastases are included in this study. The primary endpoint is 3-year overall survival (OS) after RF ablation. The secondary endpoints are the prevalence of adverse events within 4 weeks, local tumor progression rate, 1- and 5-year OS, cause-specific survival, and relapse-free survival. The recruitment of patients commenced in July 2014, and the enrolment of 45 patients is intended over the 3 years of study period.
キーワード radiofrequency ablation colorectal cancer lung metastasis
Amo Type Clinical Study Protocols
発行日 2016-08
出版物タイトル Acta Medica Okayama
70巻
4号
出版者 Okayama University Medical School
開始ページ 317
終了ページ 321
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27549681
Web of Science KeyUT 000384748600016
JaLCDOI 10.18926/AMO/54509
フルテキストURL 70_4_303.pdf
著者 Iguchi, Toshihiro| Sakurai, Jun| Hiraki, Takao| Gobara, Hideo| Fujiwara, Hiroyasu| Matsui, Yusuke| Masaoka, Yoshihisa| Kanazawa, Susumu|
抄録 This single center prospective study is being conducted to evaluate the safety of the cryoablation for patients with pathologically diagnosed painful bone and soft tissue tumors. Enrollment of 10 patients is planned over the 3-year recruitment period. Patients have related local pain after receiving medications or external radiation therapies will be included in this study. Cryoablation will be percutaneously performed under imaging guidance, and a temperature sensor will be used during treatment as necessary. The primary endpoint is prevalence of severe adverse events within 4 weeks after therapy. The secondary endpoint is effectiveness 4 weeks after the procedure.
キーワード cryoablation soft tissue and bone tumor pain safety
Amo Type Clinical Study Protocols
発行日 2016-08
出版物タイトル Acta Medica Okayama
70巻
4号
出版者 Okayama University Medical School
開始ページ 303
終了ページ 306
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27549678
Web of Science KeyUT 000384748600013
JaLCDOI 10.18926/AMO/52014
フルテキストURL 67_6_397.pdf
著者 Matsui, Yusuke| Mimura, Hidefumi| Fukazawa, Takuya| Morita, Ichiro| Suehiro, Mitsuhiko| Kawamoto, Hirofumi| Naomoto, Yoshio|
抄録 We describe an interesting clinical course of a patient who developed severe ischemic liver injury due to acute embolism of the superior mesenteric artery (SMA) and celiac artery. A 70-year-old man was hospitalized for abdominal pain and diarrhea. Abdominal computed tomography demonstrated a variant common hepatic artery arising from the SMA and multiple thromboembolic occlusions of visceral arteries, including the SMA and celiac artery. Laboratory data showed markedly elevated hepatic enzymes, which increased after admission despite the initiation of systemic anticoagulant and thrombolytic therapy. The patient was successfully treated by endovascular recanalization of the SMA occlusion via transcatheter embolus aspiration, thrombolysis, balloon angioplasty, and stent placement. Severe ischemic liver injury may occur in the setting of synchronous embolism of the SMA and celiac artery, and these phenomena may have a critical impact on the choice of treatment strategies and prognosis. Endovascular treatment appears to an effective treatment option.
キーワード superior mesenteric artery celiac artery embolism liver ischemia endovascular treatment
Amo Type Case Report
発行日 2013-12
出版物タイトル Acta Medica Okayama
67巻
6号
出版者 Okayama University Medical School
開始ページ 397
終了ページ 402
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 24356725
Web of Science KeyUT 000328915700009
JaLCDOI 10.18926/AMO/47010
フルテキストURL 65_5_287.pdf
著者 Hiraki, Takao| Gobara, Hideo| Mimura, Hidefumi| Toyooka, Shinichi| Fujiwara, Hiroyasu| Yasui, Kotaro| Sano, Yoshifumi| Iguchi, Toshihiro| Sakurai, Jun| Tajiri, Nobuhisa| Mukai, Takashi| Matsui, Yusuke| Kanazawa, Susumu|
抄録 The application of radiofrequency ablation for the treatment of lung cancer by our group at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences began in June 2001, and in the present report, we review our 10-year experience with this treatment modality at Okayama University Hospital. The local efficacy of radiofrequency ablation for the treatment of lung cancer depends on tumor size and the type of electrode used, but not on tumor type. An important factor for the prevention of local failure may be the acquisition of an adequate ablative margin. The combination of embolization and radiation therapy enhances the local efficacy. Local failure may be salvaged by repeating the radiofrequency ablation, particularly in small tumors. Survival rates after radiofrequency ablation are quite promising for patients with clinical stage I non-small cell lung cancer and pulmonary metastasis from colorectal cancer, hepatocellular carcinoma, and renal cell carcinoma. The complications caused by radiofrequency ablation can be treated conservatively in the majority of cases. However, attention should be paid to rare but serious complications. This review shows that radiofrequency ablation is a promising treatment for patients with lung cancer.
キーワード radiofrequency ablation lung cancer local efficacy survival complication
Amo Type Review
発行日 2011-10
出版物タイトル Acta Medica Okayama
65巻
5号
出版者 Okayama University Medical School
開始ページ 287
終了ページ 297
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 22037265
Web of Science KeyUT 000296116400002